TY - JOUR
T1 - Emergence of highly resistant Candida auris in the United Arab Emirates
T2 - a retrospective analysis of evolving national trends
AU - The UAE AMR Surveillance Consortium
AU - Thomsen, Jens
AU - Abdulrazzaq, Najiba M.
AU - Oulhaj, Abderrahim
AU - Nyasulu, Peter S.
AU - Alatoom, Adnan
AU - Denning, David W.
AU - Dhaheri, Fatima Al
AU - Menezes, Godfred Antony
AU - Moubareck, Carole Ayoub
AU - Senok, Abiola
AU - Everett, Dean B.
AU - Pal, Agnes Maria Dr.
AU - Hammadi, Ahmed Abdulkareem Al
AU - Ahmed, Ahmed Elhag
AU - Yousef, Ahmed F.
AU - Enshasy, Alaa M.M.
AU - Madhi, Amal Mubarak
AU - Alblooshi, Amna
AU - Podbielski, Andreas
AU - Nabi, Anju
AU - Poddar, Anup Shashikant
AU - Jha, Arun Kumar
AU - Marzooqi, Ayesha Abdulla Al
AU - Aden, Bashir
AU - Jafri, Deeba
AU - Hong, Duckjin
AU - Nsutebu, Emmanuel Fru
AU - Al-Marzooq, Farah Ibrahim
AU - Jabeen, Fouzia
AU - Selvaraj, Francis Amirtharaj
AU - Wahab, Ghada Abdel
AU - Khoder, Ghalia Abdul Khader
AU - Patil, Gitanjali Avishkar
AU - Menezes, Godfred A.
AU - Muhammad, Hadayatullah Ghulam
AU - Ahmad, Hafiz
AU - Ismail, Hala Ahmed Fouad
AU - Khalifa, Hazim
AU - Alzabi, Husein
AU - Alhashami, Ibrahim Alsayed Mustafa
AU - Lazreg, Imene
AU - Akthar, Irfaan
AU - Stelling, John
AU - Kayaf, Kaltham Ali
AU - Diddi, Kavita
AU - Ramabhadran, Krishnaprasad
AU - Dabal, Laila Al
AU - Sheek-Hussein, Mohamud M.
AU - Khan, Mushtaq
AU - Babiker, Zahir Osman
N1 - Publisher Copyright:
© 2024 Thomsen, Abdulrazzaq, Oulhaj, Nyasulu, Alatoom, Denning, Al Dhaheri, the UAE AMR Surveillance Consortium, Menezes, Moubareck, Senok and Everett.
PY - 2023/1/1
Y1 - 2023/1/1
N2 - Introduction: The Centers for Disease Prevention and Control lists Candida auris, given its global emergence, multidrug resistance, high mortality, and persistent transmissions in health care settings as one of five urgent threats. As a new threat, the need for surveillance of C. auris is critical. This is particularly important for a cosmopolitan setting and global hub such as the United Arab Emirates (UAE) where continued introduction and emergence of resistant variant strains is a major concern. Methods: The United Arab Emirates has carried out a 12 years of antimicrobial resistance surveillance (2010–2021) across the country, spanning all seven Emirates. A retrospective analysis of C. auris emergence from 2018–2021 was undertaken, utilising the demographic and microbiological data collected via a unified WHONET platform for AMR surveillance. Results: Nine hundred eight non-duplicate C. auris isolates were reported from 2018–2021. An exponential upward trend of cases was found. Most isolates were isolated from urine, blood, skin and soft tissue, and the respiratory tract. UAE nationals nationals comprised 29% (n = 186 of 632) of all patients; the remainder were from 34 other nations. Almost all isolates were from inpatient settings (89.0%, n = 809). The cases show widespread distribution across all reporting sites in the country. C. auris resistance levels remained consistently high across all classes of antifungals used. C. auris in this population remains highly resistant to azoles (fluconazole, 72.6% in 2021) and amphotericin. Echinocandin resistance has now emerged and is increasing annually. There was no statistically significant difference in mortality between Candida auris and Candida spp. (non-auris) patients (p-value: 0.8179), however Candida auris patients had a higher intensive care unit (ICU) admission rate (p-value <0.0001) and longer hospital stay (p < 0.0001) compared to Candida spp. (non-auris) patients. Conclusion: The increasing trend of C. auris detection and associated multidrug resistant phenotypes in the UAE is alarming. Continued C. auris circulation in hospitals requires enhanced infection control measures to prevent continued dissemination.
AB - Introduction: The Centers for Disease Prevention and Control lists Candida auris, given its global emergence, multidrug resistance, high mortality, and persistent transmissions in health care settings as one of five urgent threats. As a new threat, the need for surveillance of C. auris is critical. This is particularly important for a cosmopolitan setting and global hub such as the United Arab Emirates (UAE) where continued introduction and emergence of resistant variant strains is a major concern. Methods: The United Arab Emirates has carried out a 12 years of antimicrobial resistance surveillance (2010–2021) across the country, spanning all seven Emirates. A retrospective analysis of C. auris emergence from 2018–2021 was undertaken, utilising the demographic and microbiological data collected via a unified WHONET platform for AMR surveillance. Results: Nine hundred eight non-duplicate C. auris isolates were reported from 2018–2021. An exponential upward trend of cases was found. Most isolates were isolated from urine, blood, skin and soft tissue, and the respiratory tract. UAE nationals nationals comprised 29% (n = 186 of 632) of all patients; the remainder were from 34 other nations. Almost all isolates were from inpatient settings (89.0%, n = 809). The cases show widespread distribution across all reporting sites in the country. C. auris resistance levels remained consistently high across all classes of antifungals used. C. auris in this population remains highly resistant to azoles (fluconazole, 72.6% in 2021) and amphotericin. Echinocandin resistance has now emerged and is increasing annually. There was no statistically significant difference in mortality between Candida auris and Candida spp. (non-auris) patients (p-value: 0.8179), however Candida auris patients had a higher intensive care unit (ICU) admission rate (p-value <0.0001) and longer hospital stay (p < 0.0001) compared to Candida spp. (non-auris) patients. Conclusion: The increasing trend of C. auris detection and associated multidrug resistant phenotypes in the UAE is alarming. Continued C. auris circulation in hospitals requires enhanced infection control measures to prevent continued dissemination.
KW - Candida auris
KW - MENA
KW - UAE
KW - antifungals
KW - antimicrobial-resistance
KW - healthcare-associated infections
KW - surveillance
UR - http://www.scopus.com/inward/record.url?scp=85183662946&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85183662946&partnerID=8YFLogxK
U2 - 10.3389/fpubh.2023.1244358
DO - 10.3389/fpubh.2023.1244358
M3 - Article
C2 - 38292390
AN - SCOPUS:85183662946
SN - 2296-2565
VL - 11
JO - Frontiers in Public Health
JF - Frontiers in Public Health
M1 - 1244358
ER -